Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration

Journal of Urology

Volumn 160, Issue 5, 1998, Pages 1685-1688

  Oefelein, Michael G ^a  

^a 74th Medical Group   (United States)

Author keywords

Gonadoulin; Hormones; Prostatic neoplasms; Testosterone

Indexed keywords

GONADORELIN; GONADORELIN AGONIST; TESTOSTERONE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; DOSE CALCULATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SWEAT; TESTOSTERONE BLOOD LEVEL;

EID: 0344378213     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62383-8     Document Type: Article

References (19)

1. Labrie, F.: Endocrine therapy for prostate cancer. Endocr. Metab. Clin. N. Amer., 20: 845, 1991.
2. Pilepich, M. V., Krall, J. M., al-Sarraf, M., John, M. J., Doggert, R. L., Sause, W. T., Lawton, C. A., Abrams, R. A., Rotman, M. and Rubin, P.: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology, 45: 616, 1995.
3. Zelefsky, M. J., Leibel, S. A., Burman, C. M., Kutcher, G. J., Harrison, A., Happersett, L. and Fuks, Z.: Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int. J. Rad. Oncol. Biol. Phys., 29: 755, 1994.
4. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr. and Puras-Baez, A. for the Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer. J. Urol., 154: 424, 1995.
5. Akakura, K., Bruchovsky, N., Goldenberg, S. L., Rennie, P. S., Buckley, A. R. and Sullivan, L. D.: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer, 71: 2782, 1993.
6. Klotz, L. H., Herr, H. W., Morse, M. J. and Whitmore, W. F., Jr.: Intermittent endocrine therapy for advanced prostate cancer. Cancer, 58: 2546, 1986.
7. Goldenberg, S. L., Bruchovsky, N., Gleave, M. E., Sullivan, L. D. and Akakura, K.: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology, 45: 839, 1995.
8. Gleave, M., Bruchovsky, N., Bowden, M., Goldenberg, L. and Sullivan, L. D.: Intermittent androgen suppression prolongs time to androgen independent progression in the LNCaP prostate tumor model. J. Urol., part 2, 151: 457A, abstract 919, 1994.
9. Health Care Financing Administration: BESS procedure data, 1996.
10. Dijkman, G. A., del Moral, P. F., Plasman, J. W., Kums, J. J., Kums, J. J., Delaere, K. P., Debruyne, F. M., Hutchinson, F. J. and Furr, B. J.: A new extra long acting depot preparation of the LH-RH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer. J. Steroid Biochem. Mol. Biol., 37: 933, 1990.
11. Debruyne, F. M., Dijkman, G. A., Lee, D. C., Witjes, W. P., del Moral, F., Karthaus, H. F., Van der Mejden, A. P., Plasman, J. W., Pull, H. C., Kums, J. J., Idenra, J. G., Hoefakker, J. W., Heijbroek, R. P., Kil, P. J. and Khoe, G. S.: A new long acting formulation of the luteinizing hormone-releasing hormone analogue, goserelin: results of studies in prostate cancer. J. Urol., 155: 1352, 1996.
12. Wechse, H. W., Zerbib, M., Pagano, F. and Cootcoat, M. J.: Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate IM and 3M depot in patient with advanced prostatic cancer. Eur. Urol., suppl., 30: 7, 1996.
13. Kienfe, E. and Lrubben, G.: Efficacy and safety of leuprolein acetate depot for prostate cancer. The German Leuprorelin study group. Urol. Int., suppl., 56: 23, 1996.
14. Smals, A. G. H., Kloppenborg, P. W. and Benraad, T. J.: Circannual cycle in plasma testosterone levels in man. J. Clin. Endocr. Metab., 42: 979, 1976.
15. Lin, B. J. T., Chen, K., Chen, M. and Chang, L. S.: The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostate cancer. Urology, 43: 834, 1994.
16. Montgomery, B. T., Young, C. Y., Bilhartz, D. L., Andrews, P. E., Prescott, J. L., Thompson, N. F. and Tindall, D. J.: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate, 21: 63, 1992.
17. Zelefsky, M. J., Leibel, S. A., Wallner, K. E., Whitmore, W. F. Jr. and Fuks, Z.: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J. Clin. Oncol., 13: 459, 1995.
18. Zagars, G. K., Pollack, A. and von Eschenbach, A. C.: Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology, 49: 327, 1997.
19. Hellman, L., Bradlow, H. L., Freed, S., Levin, J., Rosenfeld, R. S., Whitmore, W. F. and Zumoff, B.: The effects of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J. Clin. Endocr. Metab., 45: 788, 1978.